Glaucoma, Ocular Hypertension
Conditions
Keywords
Real world, observational, retrospective, database analysis
Brief summary
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav * Greater than 18 years old * Diagnosed with glaucoma or ocular hypertension * Registered at the primary care practice for \> 12 months
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency distribution of persistent and non-persistent patients across study cohorts | 12 months |
| Frequency distribution of switchers, re-starters and discontinuing patients as well as patients commencing add-on therapy across the study cohorts | 12 months |
| Time to discontinuation of each cohort | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Prostaglandin mono-therapies | 12 months |
| Age and sex: Townsend Score of social deprivation, time since first THIN diagnosis of glaucoma or ocular hypertension | 12 months |
| presented who had had (i) a 12 month history of any of the diseases or (ii) had had a history of any of the diseases. | 12 months |
| The cohort of patients which were evaluated in this study were investigated for the presence of history of disease for asthma, cardiovascular disease, diabetes, renal failure and systemic hypertension. The number of patients in each cohort were | 12 months |
| Procedures: Laser, Trabeculectomy, viscocanalostomy, deep sclerectomy | 12 months |
| Ocular Pharmacological Treatments: Beta-blockers and Alpha-agonists | 12 months |
Outcome results
None listed